CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

BACKGROUND: Osimertinib is an oral, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor activating mutation (EGFRm) and the resistance mutation (T790M) that is FDA approved for patients with EGFR mutant lung cancer. The synergism between Osimertinib and rad...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Rauf, Yasmeen, Kotecha, Rupesh, Fadul, Camilo, Evanoff, Wendi, Suh, John, Chao, Samuel, Murphy, Erin, Yu, Jennifer, Angelov, Lilyana, Barnett, Gene, Mohammadi, Alireza, Ahluwalia, Manmeet
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Clinical Trials: Immunologic
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.156
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares